Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 5.715 mg (equivalent: atomoxetine, qty 5 mg) - capsule, hard - excipient ingredients: titanium dioxide; magnesium stearate; gelatin; pregelatinised maize starch; colloidal anhydrous silica; croscarmellose sodium; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine gxp is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 5.715 mg (equivalent: atomoxetine, qty 5 mg) - capsule, hard - excipient ingredients: magnesium stearate; colloidal anhydrous silica; gelatin; titanium dioxide; iron oxide yellow; pregelatinised maize starch; croscarmellose sodium; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine genpar is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 68.58 mg (equivalent: atomoxetine, qty 60 mg) - capsule, hard - excipient ingredients: magnesium stearate; gelatin; titanium dioxide; croscarmellose sodium; colloidal anhydrous silica; pregelatinised maize starch; indigo carmine; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine gppl is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 11.43 mg (equivalent: atomoxetine, qty 10 mg) - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; titanium dioxide; gelatin; croscarmellose sodium; colloidal anhydrous silica; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine gppl is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 11.43 mg (equivalent: atomoxetine, qty 10 mg) - capsule, hard - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; gelatin; titanium dioxide; magnesium stearate; pregelatinised maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine genpar is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 20.574 mg (equivalent: atomoxetine, qty 18 mg) - capsule, hard - excipient ingredients: gelatin; magnesium stearate; colloidal anhydrous silica; pregelatinised maize starch; croscarmellose sodium; titanium dioxide; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine genpar is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 5.715 mg (equivalent: atomoxetine, qty 5 mg) - capsule, hard - excipient ingredients: magnesium stearate; gelatin; iron oxide yellow; pregelatinised maize starch; croscarmellose sodium; titanium dioxide; colloidal anhydrous silica; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine ch is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 5.715 mg (equivalent: atomoxetine, qty 5 mg) - capsule, hard - excipient ingredients: gelatin; croscarmellose sodium; iron oxide yellow; magnesium stearate; colloidal anhydrous silica; pregelatinised maize starch; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine gppl is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 20.574 mg (equivalent: atomoxetine, qty 18 mg) - capsule, hard - excipient ingredients: magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; gelatin; iron oxide yellow; pregelatinised maize starch; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine gppl is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atomoxetine hydrochloride, quantity: 45.72 mg (equivalent: atomoxetine, qty 40 mg) - capsule, hard - excipient ingredients: colloidal anhydrous silica; gelatin; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; indigo carmine; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - atomoxetine gppl is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older, adolescents and adults.